Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03174626
Other study ID # Pro00079526
Secondary ID
Status Completed
Phase N/A
First received May 31, 2017
Last updated December 28, 2017
Start date May 3, 2017
Est. completion date August 30, 2017

Study information

Verified date May 2017
Source Duke University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of the pilot is to test the feasibility of developing and implementing the Williams LifeSkills Cancer Care (WLSCC) and examining its preliminary impact on caregiver well-being and patient well-being. The study is a two-arm randomized intervention pilot (WLSCC vs. Usual Care [UC]) with data collection at baseline, immediately after training, and 2 weeks after completing the training. Study setting is at the breast and thoracic cancer clinics at the Duke Cancer Clinic. A total of 40 cancer patients (20 breast cancer patients and 20 lung cancer patients) and their caregivers (for a total N of 80) will be recruited for the pilot. The WLSCC will involve six 30-minute phone sessions and will encompass the application of 10 psychosocial skills within the context of cancer caregiving. Descriptive statistics will be used to detail recruitment/retention rate, fidelity rate, and the baseline demographic and clinical characteristics for the total sample and each group. Plots of the individual trajectories (within-person scores over time) will be used to identify the pattern(s) of change over time, and assess between-person variability in baseline values (intercepts) and trajectories (slopes). This study carries minimal risk to study participation.


Description:

The pilot's specific aims are to:

1. Test the feasibility of (a) recruiting lung and breast cancer patients and their caregivers (hereafter, "dyads) at the Duke Cancer Center (DCC) outpatient clinic; (b) training interventionists to deliver the WLSCC protocol; (c) delivering the WLSCC protocol by phone.

2. Examine the immediate and two-week impact of the WLSCC on caregiver quality of life, anxiety and depression, caregiving preparedness, and social support as well as patient's well-being (Functional Assessment of Cancer Therapy.

Design and Procedures The pilot is two-arm randomized intervention pilot (WLSCC vs. Usual Care [UC]) with data collection at baseline (T1), immediately after training (T2), and 2 weeks after completing the training (T3). Caregivers will have an option to receive the WLCCC protocol, should they wish, after the data collection period. A stratified randomization will be conducted with stratifying variable being type of cancer and the block size will be 2.

The pilot setting is at the breast and thoracic cancer clinics at the DCC, Durham, NC. The WLSCC will involve approximately six 30-minute phone sessions between the caregiver and interventionist. The six calls will be delivered within three weeks of consent and will use intervention scripts for standardization of delivery.

The training will use the WLS format to assess issues and discuss strategies for cancer care including caregiver stress management. The context of discussion will be tailored by using the cancer issues endorsed by the cancer patient at baseline data collection. In delivering the interactive WLSCC training, the interventionist will preface each session by stating that the protocol is designed to enable them to cope more effectively with demanding caregiving situations and stressful life situations, to improve their relationships with others, and to increase the proportion of positive thoughts and feelings in their daily lives. The interventionist will frequently prompt the caregiver to raise questions that pertain to their situation (using cancer symptoms endorsed by cancer patient at baseline survey). At the end of each telephone session, the interventionist will request for the caregiver to complete log entries to provide an opportunity to reflect or put into action the WLSCC psychosocial skills taught in each session.

Subject Recruitment & Compensation:

The study team will review every week the list of adult patients who are scheduled for an outpatient visit at DCC Breast Cancer Clinic and Thoracic Clinic. For those who initially meet the criteria of aged 18 years and above and with primary breast or thoracic cancer diagnosed less than a year of the scheduled visit, the team will send an invite letter by mail to describe the study and invite their participation. A number will be provided that the patient or caregiver can call to decline participation. If no phone call or voice message is received on the opt-out number after 2 weeks of mailing the letter, the study staff will make plans to approach patient and family/friend during the visit to determine further eligibility for participation.

The study staff will visit the Duke Breast and Thoracic cancer clinic at least three times a week. She/he will approach patients who have not opted out of the study to determine if the family/friend accompanying the patient meets the definition of a caregiver for this study. If yes, the study staff will explain the study including the possibility that the dyad maybe assigned to either the WLSCC or UC group. If a working telephone number is assured and the dyads show interest in study participation, consent will be obtained from the dyad. After consent is obtained, baseline data (T1) for measures will be obtained. Using a laptop, the study staff will access study database and measures using the secure Duke server. He/she will ask questions in the baseline measures and responses will be directly entered to the study database. Thereafter, the study staff will assign the dyad a number that is randomly determined by a computer program. Each number from 1-40 will be assigned as either WLSCC or UC. The interventionist will call the caregiver at the scheduled first session. Before the first call ends, schedules for calls 2 to 6 will be established with the caregiver.

All follow-up data will be collected by phone. Follow-up data collection for T2 will be on the date of the last phone call for the WLSCC group and 3 weeks after consent was obtained in the UC group. T3 data will be collected two weeks after T2 data were collected in the WLSCC group and five weeks after consent in the UC group.

Data Analysis & Statistical Considerations:

Descriptive statistics will be used to detail recruitment/retention rate, fidelity rate, and the baseline demographic and clinical characteristics for the total sample and each group. For each caregiver and patient outcome measure, descriptive statistics will be calculated at baseline and at each follow-up. Plots of the individual trajectories (within-person scores over time) will be used to identify the pattern(s) of change over time, and assess between-person variability in baseline values (intercepts) and trajectories (slopes).Hierarchical mixed-effects models will be used to delineate and summarize trends and relationships in the data while nesting for dyads. This pilot study will focus on estimating effective size for WLSCC rather than statistical significance testing dues to the exploratory nature of the pilot study. When statistical testing is conducted, non-directional tests will be performed with level of significance set at 0.10.


Recruitment information / eligibility

Status Completed
Enrollment 7
Est. completion date August 30, 2017
Est. primary completion date August 30, 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patients are those with a confirmed medical diagnosis of breast or thoracic cancer regardless of stage and followed at DCC for management.

- The cancer diagnosis should have been made less than a year from the next scheduled appointment to the DCC.

- The caregiver is defined as unpaid individuals involved in assisting the cancer patient with activities of daily living and/or medical tasks.

- Patients and caregivers must be able to hear, read, and write in English; oriented to place, person, and time; and have an active telephone service, either cellular or landline.

Exclusion Criteria:

- Excluding patients and caregivers who are less than 18 years of age

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
WLSCC
Briefly, WLSCC contents are as follows: Psychosocial skill 1: Increase objectivity and awareness of thoughts and feelings in a distressing situation and learning the technique of a log entry; Psychosocial skill 2: Evaluate the situation to decide whether to change one's reactions or to take actions; Psychosocial skill 3: Increase the positive and the sense of meaning in your life; Psychosocial skill 4: Deflection strategies; Psychosocial skill 5: Take action when action is called for; Psychosocial skill 6: Assertion; Psychosocial skill 7: Saying "No"; Psychosocial skill 8 : Communication; Psychosocial skill 9: Become a better listener; Psychosocial skill 10: Empathy.
Other:
Usual Care
No training provided. After data collection period is over, participants have the option to receive the WLSCC training

Locations

Country Name City State
United States Duke Cancer Center Durham North Carolina

Sponsors (1)

Lead Sponsor Collaborator
Duke University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Feasibility of recruitment of dyads for the WLSCC Intervention Feasibility of recruiting as measured by the number of dyads approached per clinic visit 6 months
Primary Feasibility of agreeing to participate in the WLSCC study Feasibility of recruiting as measured by the number of yes vs no to study participation 6 months
Primary Feasibility of participating in phone calls for the study Feasibility of recruiting as measured by the rate of participation in phone calls 6 months
Primary Feasibility of recruitment and completion of measures Feasibility of recruiting as measured by the completion of outcome measures including baseline demographics (please see below under secondary outcome measures for list of outcome measures) 6 months
Primary Feasibility of recruitment longevity for the WLSCC Intervention Feasibility of recruiting as measured by the attrition rate at the end of data collection 6 months
Primary Feasibility of recruitment for the WLSCC study for control group Feasibility of recruiting as measured by the number of caregivers in the usual care who elect to receive the WLSCC protocol 6 months
Primary Feasibility of training interventionist to deliver the WLSCC Intervention Feasibility of interventionist training as measured by the number of hours required to prepare the interventionists 4 weeks
Primary Fidelity to the intervention protocol Fidelity rate as measured by the fidelity of intervention checklist 6 months
Primary Feasibility of delivery of the WLSCC protocol by phone Feasibility of delivering the WLSCC protocol by phone as measured by the rate of participation in phone calls 3 weeks
Primary Feasibility of delivery duration of the WLSCC protocol by phone Feasibility of delivering the WLSCC protocol by phone as measured by the duration of each phone call 3 weeks
Secondary Cancer Caregiver Quality of Life [CQOLC] 35 items - 5-pt Likert scale; Sum of all item scores; higher scores mean better quality of life 15 minutes
Secondary Hospital Anxiety and Depression Scale (HADS) 7 on anxiety and 7 on depression; Sum of item scores on anxiety and depression; 11 and 21 "cases", 8 and 10 "borderline cases", and 0 and 7 as "non-cases" 5 minutes
Secondary Preparedness in Caregiving 8 items, 5-pt Likert scale (0 - 4); Sum of item scores divide by number of items; higher total score denotes higher preparedness 5 minutes
Secondary Multidimensional Scale of Perceived Social Support 7 pt Likert scale; Sum of item scores, then divide by number of items; higher score denotes higher perceived support 5 minutes
Secondary Functional Assessment of Cancer Therapy [FACT-G] 27 items, 5-point Likert scale; Sum of subscale scores; higher score, the better quality of life 15 minutes
See also
  Status Clinical Trial Phase
Recruiting NCT05346796 - Survivorship Plan HEalth REcord (SPHERE) Implementation Trial N/A
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT04867850 - Effect of Behavioral Nudges on Serious Illness Conversation Documentation N/A
Enrolling by invitation NCT04086251 - Remote Electronic Patient Monitoring in Oncology Patients N/A
Completed NCT01285037 - A Study of LY2801653 in Advanced Cancer Phase 1
Completed NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Completed NCT00062842 - Study of Irinotecan on a Weekly Schedule in Children Phase 1
Active, not recruiting NCT04548063 - Consent Forms in Cancer Research: Examining the Effect of Length on Readability N/A
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT04349293 - Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways N/A
Terminated NCT02866851 - Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy N/A
Active, not recruiting NCT05304988 - Development and Validation of the EFT for Adolescents With Cancer
Completed NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Completed NCT03109041 - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source Phase 1
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Recruiting NCT06206785 - Resting Energy Expenditure in Palliative Cancer Patients
Recruiting NCT05318196 - Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases